Susanne Osanto

Leiden University Medical Center — Netherlands

Immunology and Microbiology · Life Sciences

45h-index8.0kcitations142works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(26), Prostate Cancer Treatment and Research(16), Testicular diseases and treatments(14), Venous Thromboembolism Diagnosis and Management(12), Cancer Immunotherapy and Biomarkers(11)

Publications142 total

Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review
EClinicalMedicine·2024· 1 citedOpen Access
Quantitative ultrasound of the calcaneus (QUS): A valuable tool in the identification of patients with non-metastatic prostate cancer requiring screening for osteoporosis
Bone Reports·2023· 1 citedOpen Access
In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
The Oncologist·2022Open Access
Risk of osteoporosis in testicular germ cell tumour survivors: A systematic review of the literature
BJUI Compass·2022· 2 citedOpen Access
Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin·2022· 9 citedOpen Access
Sexual and fertility-related adverse effects of medicinal treatment for cancer; a national evaluation among medical oncologists
Supportive Care in Cancer·2022· 5 citedOpen Access
Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study
European Journal of Internal Medicine·2021· 1 citedOpen Access
Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients
Histopathology·2021· 18 citedOpen Access
An Educational Need Regarding Treatment-Related Infertility and Fertility Preservation: a National Survey Among Members of the Dutch Society for Medical Oncologists
Journal of Cancer Education·2021· 4 citedOpen Access
An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
Pharmacology Research & Perspectives·2021· 4 citedOpen Access
Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
The Oncologist·2021· 29 citedOpen Access
Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients
Modern Pathology·2021· 21 citedOpen Access
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers
Clinical Genitourinary Cancer·2020· 21 citedOpen Access
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology·2020· 487 citedOpen Access
Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients
Modern Pathology·2020· 52 citedOpen Access
Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250]
European Urology·2020· 16 citedOpen Access
Clinicopathological characteristics of glomeruloid architecture in prostate cancer
Modern Pathology·2020· 14 citedOpen Access
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†
European Urology·2019· 189 citedOpen Access
Efficacy of enzalutamide in hormone-sensitive metastatic prostate cancer: Clinical utility of 18F-choline PET and whole body MRI
Annals of Oncology·2019Open Access
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
Annals of Oncology·2019· 180 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Nir I. Weijl(8), Rogier M. Bertina(8), Peter I. Schrier(7), F. J. Cleton(6), Margot Tesselaar(5), Daniel Castellano(4), Yohann Loriot(4), Andrea Necchi(4), Joaquim Bellmunt(4), Frits R. Rosendaal(3), Margitta Retz(3), Theo M. de Reijke(3), Hein Putter(3), Rob C.M. Pelger(3), A.D. Tates(3), Jeanet W. Blom(2), Thomas Powles(2), Michiel S. van der Heijden(2), Se Hoon Park(2), Jae‐Lyun Lee(2)